PDXP and myeloid sarcoma: In addition, one of 47 (2.1%) patients with type 1 diabetes (three of 72 (4.1%) patients with autoimmune Addison's disease or APS and two of 47 (4.5%) MS patients had autoantibodies against PDXP (Figure 4) (P=0.008 when comparing all four control groups with all cancer patients).